|
Orthologous residues
|
|
c‑Raf (human): S296‑p, c‑Raf (mouse): S296‑p, c‑Raf (rat): S296‑p, c‑Raf (chicken): S296‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
2D analysis, [32P] bio-synthetic labeling, mass spectrometry, mutation of modification site, phospho-antibody, phosphoamino acid analysis, western blotting
|
|
Relevant cell lines - cell types - tissues:
COS (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
monkey
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK1 (human)
|
phospho-antibody, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, activation of upstream enzyme
|
|
|
|
Comments:
phosphoantibody is for S296 only.
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
|
EGF
|
ERK1 (human)
|
|
augment treatment-induced increase
|
|
|
U0126
|
EGF
|
|
|
inhibit treatment-induced increase
|
|
|
siRNA
|
|
|
|
inhibit treatment-induced increase
|
Erk1/2 siRNA
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced
|
|
Comments:
phosphorylation of S289, S296, and S301 sustains and increases kinase activity
|